History

  • BRIM Founded
  • Series A (USD 4M)
  • BRM132 In-censed
  • Series B (USD 26M)
  • PDSP Platform In-licensed
  • BRM421 U.S. IND Approval
  • BRM421 U.S. FIH Study
  • BRM132 U.S. IND Approval
  • Series C (USD 6M)
  • BRM421 U.S. SIH Study Completed
  • BRM521 Pre-clinical Studies On-going
  • BRM421 CN Right Licensed to CGP
  • Subsidiary Ascendo Biotech Formed (raised USD 12M)